MedTrace Logo

Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Psoriasis

NCT06555497 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2024-08-16

No results posted yet for this study

Summary

A pilot study on the formulation of topical methotrexate was conducted. Patients after baseline evaluation were randomly placed into either topical 1% methotrexate gel or clobetasol propionate 0.05% ointment which was applied for 6 weeks. PASI score was assessed at two-week intervals for a total of eight weeks. Blood chemistry parameters, whole abdomen ultrasound, and adverse drug reactions while on treatment and after eight weeks were monitored as secondary outcome measures.

Conditions

Interventions

DRUG

topical 1% methotrexate gel

topical 1% methotrexate gel

DRUG

clobetasol propionate 0.05% ointment

clobetasol propionate 0.05% ointment

Sponsors & Collaborators

  • Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium

    lead OTHER

Principal Investigators

  • John Benjamin B Gochoco, MD · Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06555497 on ClinicalTrials.gov